Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dyslipidemia

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 26 articles: HTML format

Single Articles

September 2024
1. WATTS GF, Rosenson RS, Hegele RA, Goldberg IJ, et al
   Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
   N Engl J Med. 2024 Sep 2. doi: 10.1056/NEJMoa2409368.
   PubMed     Abstract available
   
   
   August 2024
2. FABBRINI E, Rady B, Koshkina A, Jeon JY, et al
   Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD.
   N Engl J Med. 2024;391:475-476.
   PubMed    
   
   
   May 2024
3. ROSENSON RS, Gaudet D, Hegele RA, Ballantyne CM, et al
   Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
   N Engl J Med. 2024 May 29. doi: 10.1056/NEJMoa2404147.
   PubMed     Abstract available
   
   
   
4. BALLANTYNE CM, Vasas S, Azizad M, Clifton P, et al
   Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
   N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143.
   PubMed     Abstract available
   
   
   April 2024
5. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
   Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
   N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
   PubMed     Abstract available
   
   
   
6. WATTS GF
   Shooting the Messenger to Treat Hypertriglyceridemia.
   N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMe2402653.
   PubMed    
   
   
   
7. STROES ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, et al
   Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
   N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2400201.
   PubMed     Abstract available
   
   
   February 2024
8. ALEXANDER VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, et al
   Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia.
   N Engl J Med. 2024;390:476-477.
   PubMed    
   
   
   April 2023
9. ALEXANDER JH
   Benefits of Bempedoic Acid - Clearer Now.
   N Engl J Med. 2023;388:1425-1426.
   PubMed    
   
   
   November 2022
10. O'DONOGHUE ML, Rosenson RS, Gencer B, Lopez JAG, et al
    Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
    N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2211023.
    PubMed     Abstract available
    
    
    
11. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
    PubMed     Abstract available
    
    
    September 2022
12. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    PubMed     Abstract available
    
    
    July 2021
13. BJORNSTAD P, Drews KL, Caprio S, Gubitosi-Klug R, et al
    Long-Term Complications in Youth-Onset Type 2 Diabetes.
    N Engl J Med. 2021;385:416-426.
    PubMed     Abstract available
    
    
    March 2021
14. GIBBONS GH, Seidman CE, Topol EJ
    Conquering Atherosclerotic Cardiovascular Disease - 50 Years of Progress.
    N Engl J Med. 2021;384:785-788.
    PubMed    
    
    
    February 2021
15. RAAL FJ, Gaudet D, Gusarova V
    Evinacumab for Homozygous Familial Hypercholesterolemia. Reply.
    N Engl J Med. 2021;384:e17.
    PubMed    
    
    
    
16. XU HG
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    
    
    
    
17. LUO F, Das A, Fang Z
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    
    
    
    
18. AGIRBASLI M
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    
    
    
    January 2021
19. GAUDET D, Ruzza A, Santos RD
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. Reply.
    N Engl J Med. 2021;384:84-85.
    PubMed    
    
    
    
20. SINGH A, Mittal S, Kazimuddin M
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:84.
    PubMed    
    
    
    December 2020
21. MARTIN SS
    Factoring in ANGPTL3 When LDL Is Refractory.
    N Engl J Med. 2020;383:2385-2386.
    PubMed    
    
    
    November 2020
22. SHAW AT, Bauer TM, de Marinis F, Felip E, et al
    First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    N Engl J Med. 2020;383:2018-2029.
    PubMed     Abstract available
    
    
    
23. ROSENSON RS, Burgess LJ, Ebenbichler CF, Baum SJ, et al
    Evinacumab in Patients with Refractory Hypercholesterolemia.
    N Engl J Med. 2020 Nov 15. doi: 10.1056/NEJMoa2031049.
    PubMed     Abstract available
    
    
    October 2020
24. DE FERRANTI SD
    Evolocumab in Children with Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020;383:1385-1386.
    PubMed    
    
    
    August 2020
25. SANTOS RD, Ruzza A, Hovingh GK, Wiegman A, et al
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019910.
    PubMed     Abstract available
    
    
    March 2020
26. RAAL FJ, Kallend D, Ray KK, Turner T, et al
    Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa1913805.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.